AmCyte Presents Promising Adult Stem Cell Data at 7th Annual Rachmiel Levine Diabetes and Obesity Symposium.

LOS ANGELES -- AmCyte Inc. (www.amcyte.com), a leader in encapsulated islet replacement and pancreatic adult stem cells, announced it will present research and development data from its Regenerated Islet Program at the 7th Annual Rachmiel Levine Diabetes and Obesity Symposium, Advances in Diabetes Research: From Cell Biology to Cell Therapy.

AmCyte has developed an extensive proprietary adult stem cell platform allowing endocrine progenitor cells to be multiplied and matured into insulin producing beta cells. Coupled with its clinically tested encapsulation technology, AmCyte's efforts to date represent the forefront of novel cell therapy approaches to treating diabetes.

The poster entitled "Proliferation and In Vivo Differentiation of Selected Adult Human Pancreatic Endocrine Progenitor Cells," builds on NCAM/CD56 selection methods developed at AmCyte and investigates multiple maturation paradigms utilizing in vivo differentiation models.

"We feel that these studies are very important as we are expanding the endocrine progenitors several million fold and are able to detect human c-peptide circulating in the transplanted mice," said Dr. Wen Tsang, Senior Vice President Research & Development. "Although the results are still preliminary, we are moving in the right direction to generate enough insulin producing cells for a cell therapy treatment of diabetes. AmCyte's successful ongoing clinical trial without long-term immune suppression has shown that transplanted encapsulated islets are protected from the patient's immune system. At this point we are establishing the technology that will allow us to move into large scale clinical trials."

AmCyte Inc., located in Santa Monica, California, specializes in adult stem cell research with the goal of treating diabetes with islet replacement therapy. AmCyte has developed novel encapsulation technology to allow transplantation of insulin-producing islets without chronic immune suppression. The company is developing Regenerated Islets utilizing its novel adult stem cell technology to scale up the supply of transplantable islets to meet patient needs.